CDK
CDK (Cyclin-Dependent Kinase) inhibitors are compounds that block the activity of CDKs, a group of protein kinases that regulate the cell cycle, transcription, and other cellular processes. CDKs are activated by binding to cyclins, and their activity is crucial for the progression of cells through different phases of the cell cycle. Inhibiting CDKs can halt cell division, leading to cell cycle arrest and apoptosis, particularly in cancer cells where CDKs are often dysregulated. CDK inhibitors are widely used in cancer research and have therapeutic potential in treating various cancers. At CymitQuimica, we provide a comprehensive selection of high-quality CDK inhibitors to support your research in cell cycle control, cancer, and therapeutic development.
Found 543 products of "CDK"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
CLK1/2-IN-1
CAS:CLK1/2-IN-1 is a CLK1 and CLK2 inhibitor and it also inhibits SRPK1 and SRPK2.Formula:C21H20F3N7OPurity:98%Color and Shape:SolidMolecular weight:443.42CDK1-IN-3
CDK1-IN-3 is a selective inhibitor targeting CDK1 (36.8 nM), CDK2 (305.17 nM), CDK5 (369.37 nM); used in cancer research.Formula:C28H25ClF3N5O2Color and Shape:SolidMolecular weight:555.98DDO-6079
CAS:DDO-6079 is an efficient CDC37 inhibitor. It suppresses the HSP90-CDC37 and CDC37-CDK4/6 chaperone complexes by binding to an allosteric site on CDC37. Additionally, DDO-6079 reduces the thermal stability of CDK6.Formula:C18H13ClN2O3Color and Shape:SolidMolecular weight:340.76Zeltociclib
CAS:Zeltociclib is an inhibitor of cyclin-dependent kinases (CDKs) with anti-tumor properties.Formula:C18H20F3N4O2PColor and Shape:SolidMolecular weight:412.346CDK9-IN-38
CAS:CDK9-IN-38 (compound 14) is a CDK9 inhibitor with IC50 values of 1.2 nM for wild-type CDK9 and 3.3 nM for the L156F mutant. It effectively inhibits tumor growth both in vitro and in vivo.Formula:C22H23N5O3SColor and Shape:SolidMolecular weight:437.515Haspin-IN-1
Haspin-IN-1 blocks haspin (IC50: 119 nM) and inhibits CLK1, DYRK1A, CDK9 with potential as an anticancer drug.Formula:C12H8N4O2SColor and Shape:SolidMolecular weight:272.28CDK9-IN-11
CAS:CDK9-IN-11 is a potent CDK9 inhibitor that is the ligand for the PROTAC CDK9 Degrader-1 [1].Formula:C20H25N3O4Purity:98%Color and Shape:SolidMolecular weight:371.43CDK/HDAC-IN-1
CDK/HDAC-IN-1 inhibits CDK2/4/6 & HDAC6 with IC50s: 60.9, 276, 27.2, and 128.6 nM respectively.Formula:C20H18N4O4Color and Shape:SolidMolecular weight:378.38CDK9-IN-34
CAS:CDK9-IN-34 (Compound 1b) is an inhibitor of CDK9 with an IC50 of 0.25 μM. It exhibits cytotoxicity against cancer cell lines HCT116, MCF7, and K652, with IC50 values of 1.43 μM, 3.01 μM, and 50.27 μM, respectively. Additionally, CDK9-IN-34 demonstrates antiviral activity against coronavirus 229E with an IC50 of 145.92 μM.Formula:C18H20N4Color and Shape:SolidMolecular weight:292.38CDK4/6-IN-24
CAS:CDK4/6-IN-24 (Compound A) is an inhibitor of CDK4/6 with broad-spectrum antitumor activity. It can effectively inhibit various cancer cells, exhibiting an IC50 in the submicromolar range.Formula:C32H41N7O3Color and Shape:SolidMolecular weight:571.713CDK1-IN-7
CAS:CDK1-IN-7 (compound M7) is a potent CDK1 inhibitor. It effectively suppresses the proliferation and migration of HCT116 and Lovo cells, making it a valuable tool for colorectal cancer research.Formula:C23H19ClN4O3Color and Shape:SolidMolecular weight:434.88SGC-CLK-1
CAS:SGC-CLK-1 is a potent and selective inhibitor of Cdc2-like kinases CLK1, CLK2, and CLK4. It effectively inhibits the growth of melanoma and glioblastoma cells.Formula:C19H15F3N6O2Color and Shape:SolidMolecular weight:416.36CDK8-IN-11
CAS:CDK8-IN-11 is a CDK8 inhibitor that demonstrates anti-proliferative activity against colon cancer cell lines and inhibits the activation of WNT/β-catenin.Formula:C19H15F3N4O2Purity:99.74%Color and Shape:SolidMolecular weight:388.34Ref: TM-T61742
1mg54.00€5mg114.00€10mg178.00€25mg409.00€50mg708.00€100mg982.00€1mL*10mM (DMSO)126.00€PPA-037
CAS:PPA-037 is an orally active and highly selective inhibitor of cyclin-dependent kinase 12 (CDK12). It induces the degradation of Cyclin K, thereby enhancing antiproliferative effects on tumor cells. PPA-037 holds potential for use in cancer research.Formula:C25H27N7Color and Shape:SolidMolecular weight:425.53Cdc7-IN-19
CAS:Cdc7-IN-19 (compound 1-1) is a potent CDC7 inhibitor with an IC 50 of 1.49 nM [1].Formula:C19H21N5O2Color and Shape:SolidMolecular weight:351.40CDK5-IN-2
CAS:CDK5-IN-2 (compound 15) is a highly selective CDK5 inhibitor that acts on CDK5/p25 (IC50: 0.2 nM) and CDK2/CycA (IC50: 23 nM).Formula:C29H28FN5OColor and Shape:SolidMolecular weight:481.56CDK1-IN-5
CDK1-IN-5 is a selective inhibitor for CDK1 (IC50: 42.19 nM), CDK2, CDK5, halting cancer cell growth.Formula:C27H26ClN5OSColor and Shape:SolidMolecular weight:504.05CDK2-IN-31
CAS:CDK2-IN-31 (compound I-125A) is an inhibitor of CDK2 and is utilized in cancer research.Formula:C37H52N6O5Color and Shape:SolidMolecular weight:660.85Protein kinase inhibitor 13
CAS:Protein kinase inhibitor 13 (Compound I-90) functions as a kinase inhibitor, specifically targeting kinases such as PIM-1, CDK-2, GSK-3, and SRC.Formula:C19H20FN5OSColor and Shape:SolidMolecular weight:385.458CDK12/13 ligand 1
CAS:ALK-IN-29 (compound 4c) exhibits notable inhibitory activity against tyrosine kinases such as ALK, CDK2/CyclinE1, and FAK, with the strongest inhibition observed against ALK kinase, showing a 40.63% inhibition rate at a concentration of 10 μM. ALK-IN-29 is useful for cancer research.Formula:C26H26BrN5OColor and Shape:SolidMolecular weight:504.42CDK9/PARP-IN-1
CAS:CDK9/PARP-IN-1 (compound 37) is an inhibitor of CDK9 and PARP. It demonstrates IC50 values of 118 nM for CDK9 and 107 nM for PARP1. This compound exhibits a broad-spectrum anti-proliferative effect across various cancer cell lines.Formula:C38H34F2N8O3Color and Shape:SolidMolecular weight:688.725YKL-1-116
CAS:YKL-1-116 is an effective, selective, and covalent CDK7 inhibitor.Formula:C34H38N8O3Purity:98%Color and Shape:SolidMolecular weight:606.72Protein Kinase Inhibitor 12
CAS:Protein Kinase Inhibitor 12 (compound 1-91) is protein kinase inhibitor,PIM-1, CDK-2, GSK-3, and SRC mammalian protein kinases.Formula:C14H14N4OSPurity:98.06%Color and Shape:SolidMolecular weight:286.35CDK7/12-IN-1
CAS:CDK7/12-IN-1 is a selective CDK7 (IC50: 3 nM) and CDK12 (IC50: 277 nM) inhibitor, effective against tumor growth.Formula:C25H34N8OColor and Shape:SolidMolecular weight:462.59Cimpuciclib tosylate
CAS:Cimpuciclib tosylate, a selective CDK4 inhibitor (IC50: 0.49 nM), exhibits anti-tumor activity.Formula:C37H43FN8O4SColor and Shape:SolidMolecular weight:714.85Anticancer agent 30
Anticancer agent 30 (6f-Z), a 3-arylidene-2-oxindole, selectively inhibits CDK2, showing potent anticancer potential.Formula:C22H15ClFNOColor and Shape:SolidMolecular weight:363.81PKMYT1-IN-7
CAS:PKMYT1-IN-7 (compound 7) is an orally active PKMYT1 inhibitor with IC50 values of 1.6 nM for PKMYT1 and 0.06 μM for pCDK1. It inhibits the phosphorylation of CDK1 at T14 and Y15 sites and exhibits anticancer activity both in vitro and in vivo.Formula:C17H18FN5O3Color and Shape:SolidMolecular weight:359.355Cdc7-IN-8
CAS:Cdc7-IN-8, inhibits Cdc7 kinase, key in DNA replication, and is promising for cancer research. (WO2021032170A1)Formula:C19H21N5O2Color and Shape:SolidMolecular weight:351.40Cdc7-IN-11
CAS:Cdc7-IN-11 is a potent inhibitor of Cdc7 (IC50 ≤ 1 nM) and can be used in the study of proliferative diseases.Formula:C20H22F2N4O2SColor and Shape:SolidMolecular weight:420.48CLK1/4-IN-1
CLK1/4-IN-1 inhibits Clk1/4 (IC50: 9.7/6.6 nM), curbing T24 cell growth (GI50: 1.1 μM). Potential cancer research tool.Formula:C18H14ClNO4SColor and Shape:SolidMolecular weight:375.83GSK3-IN-10
CAS:GSK3-IN-10 (Compound 4) is a multi-target inhibitor primarily affecting GSK3α and GSK3β with IC50 values of 1.0 nM and 2.0 nM, respectively. It inhibits the activation of β-catenin, enhances neuronal survival, and provides protective effects against endoplasmic reticulum stress.Formula:C17H18F2N4O3Color and Shape:SolidMolecular weight:364.347CDK4-IN-1
CAS:CDK4 inhibitor is a novel and specific CDK4/Cyclin D1 inhibitor with an IC50 of 10 nM; 1500 and 500 fold than CDK1/Cyclin B (IC50>15 uM) and CDK2/Cyclin A (IC50Formula:C22H29ClN8Purity:98%Color and Shape:SolidMolecular weight:440.97CDK1-IN-4
CDK1-IN-4 inhibits CDK1 (IC50: 44.52 nM), CDK2/CDK5 less potently, impacts cell cycle, used in cancer studies.Formula:C26H24ClN5SColor and Shape:SolidMolecular weight:474.02CDK7-IN-33
CAS:CDK7-IN-33 (Compound 148) is a CDK7 inhibitor with a Ki value of 21.75 nM. It suppresses the proliferation of A549 cells expressing CDK7WT, with a pIC50 of 7.37.Formula:C29H36N6O4SColor and Shape:SolidMolecular weight:564.699Haspin-IN-2
CAS:Haspin-IN-2 is a potent haspin inhibitor (IC50: 50 nM) and also inhibits CLK1 (IC50: 445 nM) and DYRK1A (IC50: 917 nM).Formula:C12H8N4O3Color and Shape:SolidMolecular weight:256.22Cdc7-IN-10
CAS:Cdc7-IN-10 is a potent inhibitor of Cdc7 (IC50 ≤ 1 nM) and can be used in studies of proliferative diseases.Formula:C20H22F2N4O2SColor and Shape:SolidMolecular weight:420.48DS96432529
DS96432529 is a potent and orally active bone anabolic agent through CDK8 inhibition.Formula:C18H26N4O3SColor and Shape:SoildMolecular weight:378.49GFB-12811
CAS:GFB-12811 is an orally active, selective, and potent CDK5 inhibitor, used in the study of autosomal dominant polycystic kidney disease.Formula:C22H23F4N5OPurity:98.88%Color and Shape:SolidMolecular weight:449.44LY3143921 hydrate
CAS:LY3143921 ((S)-Example 2) hydrate is an orally active CDC7 kinase inhibitor with broad in vitro anticancer activity [1].Formula:C16H14FN5O2Purity:98.43%Color and Shape:SolidMolecular weight:327.31Tanuxiciclib
CAS:Tanuxiciclib is a cyclin dependent kinase (CDK) inhibitor, specifically designed to interfere with cell cycle progression by inhibiting the activity of CDKs, which are crucial regulators of cell division.Formula:C15H13FN6OColor and Shape:SolidMolecular weight:312.308GSK-3/CDK5/CDK2-IN-1
CAS:GSK-3/CDK5/CDK2-IN-1 is an imidazole derivative compound that inhibits cdk5, cdk2, and GSK-3.it has demonstrated applications in cancer research and the study of neurodegenerative diseases [1].Formula:C21H22N4O2Color and Shape:SolidMolecular weight:362.433Tibremciclib
CAS:Tibremciclib is a cyclin-dependent kinase 4 (CDK4) inhibitor that exhibits antineoplastic properties [1].
Formula:C28H32F2N8Purity:98%Color and Shape:SolidMolecular weight:518.6YK-2168
CAS:YK-2168 is a differentiated selective inhibitor of CDK9.
Formula:C16H18ClN5Color and Shape:SolidMolecular weight:315.80Ref: TM-T200769
Discontinued product
